The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada

OBJECTIVE: Monoclonal antibodies (MAbs) such as trastuzumab and bevacizumab have become important yet expensive components of systemic cancer therapy across a variety of disease sites. We assessed the potential cost implications of adopting trastuzumab and bevacizumab therapy in the context of their...

Descripción completa

Detalles Bibliográficos
Autores principales: Drucker, A., Skedgel, C., Virik, K., Rayson, D., Sellon, M., Younis, T.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2008
Materias:
Medical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442764/
https://www.ncbi.nlm.nih.gov/pubmed/18596891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442764/
https://www.ncbi.nlm.nih.gov/pubmed/18596891

Ejemplares similares